Posts

Smart Cancer Resources & Research Guide 2026: A Patient-First Map of Diagnosis, Biomarkers, Treatment, Immunotherapy, Resistance & Integrative Oncology

Image
OneDayMD Cancer Resource Library · Network Index · Published September 17, 2026 · Last reviewed and updated September 18, 2026 (v1.1) Cancer information is no longer confined to a single textbook, treatment guideline, or hospital website — and cancer guides should not be limited to oncologists. Modern oncology now spans pathology, staging, molecular biomarkers, precision medicine, prevention, surgery, radiation, chemotherapy, targeted therapy, immunotherapy, cellular therapy, cancer metabolism, treatment resistance, supportive care, and clinical research. This OneDayMD guide brings those subjects together in one navigable resource. Rather than hundreds of disconnected articles, it offers a pathway through the evidence and links directly to deeper OneDayMD, SmartCancer, and Cancer Advisor resources. Quick Answer This page is a map, not a single treatment guide — it connects the OneDayMD network's cancer content by the question you're actually asking. Newly diagnosed...
Post a Comment
Read more

Repurposed Cancer Drugs: Case Evidence Registry and Outcomes Audit

SmartCancer | Evidence Methods Cancer patients and families increasingly encounter reports about medicines originally developed for other conditions that are being investigated or used experimentally for cancer. These reports range from peer-reviewed case studies to laboratory research, social media testimonials and claims of long-term remission. The Repurposed Cancer Drugs: Case Evidence Registry and Outcomes Audit establishes a structured framework for cataloguing these reports, tracing them to their sources, assessing the quality of the available documentation and distinguishing reported outcomes from independently verified clinical responses. Registry status and scope This page defines the registry's proposed methodology, data fields and audit rules. It does not represent a completed systematic review, a fully populated clinical registry or an independently verified collection of patient outcomes. Individual records and aggreg...
Post a Comment
Read more

Repurposed Cancer Drugs, Integrative & Precision Oncology (2026): Evidence Guide

Image
An evidence-aware guide to off-label cancer therapies, integrative oncology, precision oncology and emerging research, without hype or false promises. By Dr. Frank Yap, MD · One Day Media Network · Originally published January 2026 · Updated October 6, 2026 · Evidence reviewed to this date Quick Answer Repurposed cancer drugs are existing approved medicines tested for anti-cancer effects. As of October 2026, only one has recent randomized-trial support in a defined setting : low-dose aspirin after surgery for PI3K-pathway-altered stage I–III colorectal cancer (ALASCCA, NEJM 2025). Metformin failed in the 3,649-patient MA.32 breast cancer trial. Ivermectin, fenbendazole and mebendazole have no completed randomized trials showing cancer benefit. Repurposed drugs are adjuncts to, never replacements for, standard oncology care. Contents What this hub covers Executive summary Why repurposed drugs matter in oncology Evidence scale used on OneDayMD (CEBM Levels 1–5) Evi...
Post a Comment
Read more